DAGLA Autoantibody Detection for Neuroautoimmune Diagnosis

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current diagnostic systems face challenges in accurately distinguishing neurological conditions associated with autoantibodies from those without, particularly in differentiating autoimmune diseases from infectious diseases, which hampers effective treatment and management.

Innovation Solution

The development of methods and reagents targeting autoantibodies to DAGLA, including immobilized polypeptides, pharmaceutical compositions, and diagnostic kits, for the detection and isolation of autoantibodies in bodily fluids, utilizing techniques like ELISA and immunofluorescence to aid in diagnosing neurological disorders such as PNS, cerebellitis, epilepsy, and sclerosis.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Adaptability or versatility

If general diagnostic methods are used for neurological diseases, then a broad range of conditions can be screened, but the precision of distinguishing autoimmune diseases from other neurological conditions deteriorates

Engineering Contradiction:

Improvescreening capabilityVSAvoiddiagnostic precision

Core Design Contradiction:

Adaptability or versatilityVSMeasurement precision

Solution Approach 1:

The diagnostic approach is segmented into two distinct parts: a broad screening phase using general neurological disease markers, followed by a targeted confirmation phase using DAGLA-specific autoantibody detection. This segmentation allows the system to maintain both broad adaptability in initial screening and high precision in final diagnosis.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

DAGLA-specific autoantibody detection serves as an intermediary marker that bridges the gap between general neurological symptoms and specific autoimmune disease diagnosis. The presence of these specific autoantibodies acts as a mediator to differentiate autoimmune conditions from other neurological diseases with similar presentations.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If early diagnosis of neurological autoimmune diseases is pursued, then treatment effectiveness is improved, but the complexity of diagnostic procedures increases

Engineering Contradiction:

Improvetreatment effectivenessVSAvoiddiagnostic procedure complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The diagnostic system performs preliminary detection of DAGLA-specific autoantibodies using highly sensitive assays before initiating complex treatment protocols. This preliminary action enables early identification of autoimmune conditions, allowing treatment to begin at the optimal time without requiring complex subsequent diagnostic procedures.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

Complex mechanical and procedural diagnostic steps are replaced by sophisticated immunological assays that detect DAGLA-specific autoantibodies in patient samples. This substitution reduces procedural complexity while maintaining or improving diagnostic reliability through highly specific biological detection mechanisms.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

3Measurement precision

If specific autoantibody detection assays are developed, then diagnostic precision for autoimmune diseases is improved, but the difficulty of detecting and measuring these markers increases

Engineering Contradiction:

Improveautoantibody detection precisionVSAvoiddetection difficulty

Core Design Contradiction:

Measurement precisionVSDifficulty of detecting and measuring

Solution Approach 1:

The diagnostic assay is designed with universal applicability to detect DAGLA-specific autoantibodies across different patient populations and disease presentations. The assay uses standardized protocols and reagents that can be implemented in various laboratory settings, reducing detection difficulty while maintaining high precision through consistent performance.

Inventive Principle:

Principle #6Universality (Multi-functionality)

Solution Approach 2:

The detection method utilizes optimized parameters including specific antibody concentrations, incubation temperatures, and detection thresholds that maximize precision for DAGLA autoantibody detection. These parameter optimizations reduce the difficulty of detection by creating assay conditions where even low levels of specific autoantibodies can be reliably measured.

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Enables early and accurate diagnosis of neurological autoimmune diseases by specifically detecting autoantibodies to DAGLA, facilitating appropriate treatment regimens and differentiating autoimmune conditions from infectious ones, thereby improving patient outcomes.

Implementation Method 1

detecting in a sample from a patient an autoantibody binding to DAGLA

Methodology Applied

Scientific EffectAntigen-antibody binding:

Data Source

PatentUS10989712B2Diagnosis of a neuroautoimmune disease

Publication Date: 2021.04.27 EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA

AI summary

A method is used for diagnosing a disease by detecting in a sample with antibodies from a patient an autoantibody binding to DAGLA.